Bomedemstat extension trial tests Long-Term safety for blood cancer patients

NCT ID NCT05223920

Completed Disease control Sponsor: Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at the long-term safety of bomedemstat, an oral drug, in 81 people with myeloproliferative neoplasms (MPNs) like essential thrombocythemia and primary myelofibrosis. Participants had already taken bomedemstat in a prior study. Researchers tracked side effects, spleen size, and platelet counts to see if the drug remains safe and effective over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bomedemstat (oral capsule)
What this could lead to: If successful, this study could show that bomedemstat is safe and effective for long-term control of myeloproliferative neoplasms, offering a new treatment option.
What could go wrong: This is a small, early-phase extension study with no placebo group, so results may not prove long-term benefit. Side effects are possible, and the drug may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

essential thrombocythemia primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY MYELOFIBROSIS THROMBOCYTHEMIA ESSENTIAL

Contacts and locations

Locations

Azienda Ospedaliera SS. Antonio

Alessandria, 15121, Italy
Azienda Ospedaliero Universitaria di Bologna

Pavia, 27100, Italy
Azienda Ospedaliero-Universitaria Careggi - S.O.D. Ematologia (CRIMM)

Florence, 50134, Italy
Cleveland Clinic Foundation

Cleveland, Ohio, 44195, United States
Fred Hutchinson Cancer Center

Seattle, Washington, 98109, United States
Gold Coast Hospital and Health Service

Southport, Queensland, 4215, Australia
Guy's and Saint Thomas' NHS Foundation Trus

London, SE1 9RT, United Kingdom
Middlemore Clinical Trials

Papatoetoe, Aukland, 2025, New Zealand
Ospedale di Circolo-a Fondazione Macchi

Varese, VA, 2100, Italy
Queen Mary Hospital

Hong Kong, Hong Kong
Royal Adelaide Hospital

Adelaide, South Australia, 5000, Australia
Royal North Shore Hospital

Saint Leonards, New South Wales, 2065, Australia
Royal Prince Alfred Hospital

Camperdown, New South Wales, 2050, Australia
UMPC Hillman Cancer Center

Pittsburgh, Pennsylvania, 15232, United States
Universittsklinikum Essen

Essen, 45147, Germany
University College London Hospitals NHS Foundation Trust

London, NW1 12G, United Kingdom
University of Miami Leonard M. Miller

Miami, Florida, 33136, United States
University of Michigan

Ann Arbor, Michigan, 48109, United States
Waitemata District Health Board

Takapuna, Aukland, 0622, New Zealand

More trials for these conditions

Other studies related to the condition(s) this trial covers.